Bronchial Thermoplasty News and Research

RSS

Bronchial thermoplasty is a bronchoscopic procedure to reduce the mass of airway smooth muscle and attenuate bronchoconstriction. We examined the effect of bronchial thermoplasty on the control of moderate or severe persistent asthma.

Asthmatx presents 2-year results from AIR2 Trial of bronchial thermoplasty in severe asthma

Boston Scientific Corporation today announced that its newly acquired subsidiary, Asthmatx, Inc., presented two-year results from the Asthma Intervention Research 2 (AIR2) Trial demonstrating the long-term safety and effectiveness of bronchial thermoplasty (BT) in adult patients with severe asthma.

2 Nov 2010

Boston Scientific announces completion of Asthmatx acquisition

Boston Scientific Corporation today announced the completion of its acquisition of Asthmatx, Inc. of Sunnyvale, California. The transaction follows the definitive agreement announced on September 20. Under the terms of the agreement, Boston Scientific purchased all outstanding Asthmatx shares for a total of $193.5 million. Additional payments of up to $250 million are contingent upon achievement of specified revenue-based criteria through 2019. Asthmatx is now an indirect, wholly-owned subsidiary of Boston Scientific.

27 Oct 2010

Boston Scientific announces acquisition of Asthmatx

Boston Scientific Corporation today announced the signing of a definitive merger agreement, under which Boston Scientific will acquire Asthmatx, Inc., a privately held company in Sunnyvale, California. Asthmatx designs, manufactures and markets a less-invasive, catheter-based bronchial thermoplasty procedure for the treatment of severe persistent asthma in the 6 to 8 million patients 18 years and older worldwide whose asthma is not well controlled with drugs (inhaled medications).

20 Sep 2010

AIR Trial demonstrates benefits of BT in asthma patients

Asthmatx Inc., today presented positive five-year data from the Asthma Intervention Research Trial, which evaluated the safety of bronchial thermoplasty with the Alair System. The data demonstrated the absence of clinical complications and the maintenance of stable lung function over a five year period post-BT in patients with moderate to severe asthma.

20 May 2010

CVS calls on FDA to suspend use of contaminated rotavirus vaccines

On Friday, the Food and Drug Administration (FDA) convened a panel of experts to review recent findings that rotavirus vaccines given to infants in the U.S., Rotateq, produced by Merck Pharmaceuticals and Rotarix produced by GlaxoSmithKline, are contaminated with DNA from pig viruses PCV1 and PCV2. On March 22nd the FDA Commissioner asked doctors to suspend use of the Rotarix vaccine due to the contamination. Upon additional testing, Rotateq was also found to be contaminated.

10 May 2010

Asthmatx announces first U.S. patient treated with BT delivered by Alair System

Asthmatx, Inc. reported today that doctors at Virginia Hospital Center in Arlington, Va., recently treated the first U.S. patient with bronchial thermoplasty (BT) delivered by the Alair® System, the first device-based asthma treatment approved by the U.S. Food and Drug Administration (FDA).

10 May 2010

CA-BSI can be reduced in children through quality improvement efforts: Study

Bloodstream infections associated with catheters can be significantly reduced through quality improvement efforts, possibly leading to better health outcomes and lives saved, decreased stays at the hospital and related costs, according to a new study.

4 May 2010

FDA grants Fenwal 510(k) clearance for Amicus separator with DXT

Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance for its Amicus® separator with new wireless data-export capabilities.

29 Apr 2010

Mylan Pharmaceuticals' ANDA for generic version of Flomax receives FDA approval

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Tamsulosin Hydrochloride Capsules USP, 0.4 mg, the generic version of Boehringer Ingelheim's benign prostatic hyperplasia treatment, Flomax.

29 Apr 2010

TUH, PASNAP reach tentative 4-year agreement

Temple University Hospital (TUH) and the Pennsylvania Association of Staff Nurses & Allied Professionals (PASNAP) have reached tentative 4-year contract agreements for the bargaining units that represent the Hospital's nurses and technical/professional employees, respectively.

28 Apr 2010

Alair Bronchial Thermoplasty System receives FDA approval to treat asthma in adults

The U.S. Food and Drug Administration today approved the first medical device that uses radiofrequency energy to treat severe and persistent asthma in certain adults.

28 Apr 2010

Positive results from Asthmatx's AIR2 Trial published in AJRCCM

Asthmatx Inc., developer of bronchial thermoplasty with the Alair® System, announced today the publication of positive results from its pivotal study, the Asthma Intervention Research 2 (AIR2) Trial, in the American Journal of Respiratory and Critical Care Medicine (AJRCCM).

13 Jan 2010

FDA Anesthesiology and Respiratory Therapy Devices Panel recommends approval for Asthmatx' Alair System

Asthmatx Inc., announced today that the Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee to the U.S. Food and Drug Administration (FDA) voted to recommend that the Alair® System, a device utilized in bronchial thermoplasty for the treatment of severe persistent asthma in patients 18 years and older, be found approvable with conditions.

29 Oct 2009

New asthma treatment bronchial thermoplasty improves patient quality of life

Chronic asthma sufferers may find new relief in a simple, minimally invasive outpatient procedure known as bronchial thermoplasty, which uses controlled radiofrequency-generated heat to treat the muscles of the airways, preventing them from constricting and narrowing.

18 May 2009

$1-year results of bronchial thermoplasty in refractory asthma$

1-year results of bronchial thermoplasty in refractory asthma

Asthmatx, Inc. has announced the publication of data from the Research in Severe Asthma (RISA) Trial of bronchial thermoplasty in the American Journal of Respiratory and Critical Care Medicine (AJRCCM, 2007; 176:1185-1191).

12 Feb 2008

Asthmatx completes enrollment in study of bronchial thermoplasty

Asthmatx, Inc. has announced the successful completion of enrollment in its pivotal FDA approved IDE study, the Asthma Intervention Research 2 (AIR2) Trial of the Alair, Bronchial Thermoplasty System.

22 May 2007

Bronchial thermoplasty study

A new report published in the prestigious New England Journal of Medicine (NEJM) shows that patients treated with bronchial thermoplasty, the first non-drug treatment for asthma, demonstrated an overall improvement in asthma control.

30 Mar 2007

Bronchial thermoplasty offers significant improvement for asthmatics

Asthmatic patients showed significant improvement in peak expiratory flow, airway responsiveness and number of symptom-free days after treatment with bronchial thermoplasty, a new procedure designed to reduce the ability of airway smooth muscle to narrow from inflammation.

3 May 2006